Guideline

Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection

Year of Publication

2018

Issuing Institution

World Health Organization

Links

Recommendations

7 included recommendations

WHO recommends offering treatment to all individuals (with the exception of pregnant women) diagnosed with HCV infection who are 12 years of age or older, irrespective of disease stage.

Status

Retired

Recommended in favor

Strong

Certainty of evidence

Moderate

WHO recommends the use of pangenotypic direct-acting antiviral regimens for the treatment of persons with chronic HCV infection aged 18 years and above

Status

Retired

Recommended in favor

Conditional

Certainty of evidence

Moderate

In adolescents aged 12–17 years or weighing at least 35 kg with chronic HCV, WHO recommends sofosbuvir/ledipasvir for 12 weeks in genotypes 1, 4, 5 and 6

Status

Retired

Recommended in favor

Strong

Certainty of evidence

Very low

In adolescents aged 12–17 years or weighing at least 35 kg with chronic HCV, WHO recommends sofosbuvir/ribavirin for 12 weeks in genotype 2

Status

Retired

Recommended in favor

Strong

Certainty of evidence

Very low

In adolescents aged 12–17 years or weighing at least 35 kg with chronic HCV, WHO recommends sofosbuvir/ribavirin for 24 weeks in genotype 3

Status

Retired

Recommended in favor

Strong

Certainty of evidence

Very low

In children aged less than 12 years with chronic hepatitis C, WHO recommends deferring treatment until 12 years of age

Status

Retired

Recommended against

Conditional

Certainty of evidence

Very low

In children aged less than 12 years with chronic hepatitis C, WHO recommends that treatment with interferon-based regimens should no longer be used

Status

Updated

Recommended against

Strong

Certainty of evidence

Very low